Vincenzo Mazzaferro
University of Milan
CancerInternal medicineRadiologyEndocrinologySurgeryPathologyOncologySurvival rateCirrhosisCarcinomaHepatocellular carcinomaSorafenibNeuroendocrine tumorsLiver transplantationTransplantationIn patientCancer researchMedicineBiologyGastroenterology
Publications 487
#1Massimo IavaroneH-Index: 30
#2Federica InvernizziH-Index: 31
Last. Sherrie Bhoori (University of Milan)H-Index: 26
view all 39 authors...
BACKGROUND AND AIM Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared to best supportive care (BSC) in LT-patients after sorafenib discontinuation. METHODS This observational multicenter retrospective study included LT-patients with HCC-recurrence who discontinued first-line sorafenib. Group-1 was constituted by regorafenib-treated patients, while contr...
#1Carlo Sposito (University of Milan)H-Index: 7
Last. Vincenzo Mazzaferro (University of Milan)H-Index: 89
view all 8 authors...
Cholangiocarcinoma is the second most common primary tumor of the liver. The incidence and mortality of its intrahepatic form has been increasing over the past 2 decades. Currently, the only available curative treatment for intrahepatic cholangiocarcinoma is surgical resection. There is still no prospective evidence to support neoadjuvant systemic treatments in resectable disease, while adjuvant chemotherapy with Capecitabine is currently the only recommended systemic treatment after liver resec...
#1Alessio Malacrida (University of Milano-Bicocca)H-Index: 6
#2Roberta Rigolio (University of Milano-Bicocca)H-Index: 16
Last. Mariarosaria Miloso (University of Milano-Bicocca)H-Index: 25
view all 7 authors...
Cholangiocarcinoma is the first most common cancer of the biliary tract. To date, surgical resection is the only potentially curative option, but it is possible only for a limited percentage of patients, and in any case survival rate is quite low. Moreover, cholangiocarcinoma is often chemotherapy-resistant, and the only drug with a significant benefit for patient’s survival is Gemcitabine. It is necessary to find new drugs or combination therapies to treat nonresectable cholangiocarcinoma and i...
#1Gabriela Hernandez-Meza (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 6
#2Johann von Felden (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 15
Last. Augusto Villanueva (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 63
view all 14 authors...
BACKGROUND Mutations in TERT promoter are established gatekeepers in early hepatocarcinogenesis, but little is known about other molecular alterations driving this process. Epigenetic deregulation is a critical event in early malignancies. Thus, we aimed: 1) to analyze DNA methylation changes during the transition from preneoplastic lesions to early HCC (eHCC) and to identify candidate epigenetic gatekeepers, and 2) to assess the prognostic potential of methylation changes in cirrhotic tissue. M...
3 CitationsSource
#1Ketevani Kankava (Tbilisi State Medical University)H-Index: 3
#2Patrick Maisonneuve (IEO: European Institute of Oncology)H-Index: 134
view all 15 authors...
Updates in classification of gastro-entero-pancreatic neuroendocrine neoplasms better reflect the biological characteristics of these tumours. In the present study, we analysed the characteristics of neuroendocrine tumours that could aid in a more precise stratification of risk groups. In addition, we have highlighted the importance of grade (re)assessment based on investigation of secondary tumour lesions. Two hundred and sixty-four cases of neuroendocrine tumours of gastro-entero-pancreatic or...
#1Ilaria Vicentin (University of Milan)H-Index: 3
#2Cristina MosconiH-Index: 17
Last. Vincenzo Mazzaferro (University of Milan)H-Index: 89
view all 15 authors...
Objectives null To evaluate the inter-observer reliability of modified Response Evaluation Criteria In Solid Tumours (mRECIST) of patients with hepatocellular carcinoma (HCC) undergoing neo-adjuvant treatments before liver transplant (LT). The agreement of tumor number, size, transplant criteria, and the radiological-pathological concordance were also assessed. null Methods null A total of 180 radiological studies before/after neo-adjuvant therapies performed on 90 patients prior to LT were revi...
In resectable gastric or gastroesophageal junction cancer (GC/GEJC), the powerful positive prognostic effect and the potential predictive value for a lack of benefit from the combination of adjuvant/peri-operative chemotherapy for the MSI-high status was demonstrated. Given the high sensitivity of MSI-high tumors for immunotherapy, exploratory trials showed that combination immunotherapy induces a high rate of complete pathological response (pCR), potentially achieving cancer cure without surger...
#1Aldo Rocca (UNIMOL: University of Molise)H-Index: 11
#2Federica Cipriani (UniSR: Vita-Salute San Raffaele University)H-Index: 27
Last. Luca AldrighettiH-Index: 59
view all 47 authors...
At the time of diagnosis synchronous colorectal cancer, liver metastases (SCRLM) account for 15-25% of patients. If primary tumour and synchronous liver metastases are resectable, good results may be achieved performing surgical treatment incorporated into the chemotherapy regimen. So far, the possibility of simultaneous minimally invasive (MI) surgery for SCRLM has not been extensively investigated. The Italian surgical community has captured the need and undertaken the effort to establish a Na...
#2Miguel Torres-Martin (University of Barcelona)
#2Miguel Torres-Martin (University of Barcelona)H-Index: 2
#1Carlo Sposito (University of Milan)H-Index: 7
#2Roberta Elisa RossiH-Index: 26
Last. Vincenzo MazzaferroH-Index: 89
view all 8 authors...
Background Liver metastases from neuroendocrine tumors (NETs) is an accepted indication for liver transplantation (LT). Despite strict patient selection, post-LT recurrence is observed in 30-50% of cases. Postrecurrence survival is poorly investigated as well as factors influencing postrecurrence outcomes. Methods Consecutive patients treated at a single Institution for post-LT recurrence of NET between Jan 1st, 2004 and Dec 31th, 2018 were included. Baseline patients' characteristics, data on t...